| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
72,131 |
63,278 |
$2.83M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
10,044 |
9,529 |
$661K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
7,164 |
6,951 |
$541K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,455 |
7,827 |
$527K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
20,660 |
19,757 |
$342K |
| 87428 |
|
7,160 |
6,644 |
$301K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
21,316 |
19,737 |
$293K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
3,798 |
3,702 |
$286K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
14,216 |
13,337 |
$216K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
3,133 |
2,916 |
$151K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,657 |
1,565 |
$138K |
| 99460 |
|
2,927 |
2,720 |
$123K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,156 |
4,472 |
$120K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,368 |
3,207 |
$96K |
| 90670 |
|
5,489 |
5,330 |
$63K |
| 99462 |
|
1,165 |
923 |
$27K |
| 90710 |
|
2,887 |
2,823 |
$27K |
| 90633 |
|
8,803 |
8,420 |
$23K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,610 |
1,272 |
$23K |
| 54150 |
|
326 |
296 |
$21K |
| 90723 |
|
3,355 |
3,240 |
$20K |
| 90473 |
|
878 |
847 |
$19K |
| 87807 |
|
1,115 |
1,051 |
$14K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
528 |
512 |
$13K |
| 90734 |
|
1,095 |
1,053 |
$10K |
| 90680 |
|
2,067 |
2,004 |
$8K |
| 90647 |
|
3,342 |
3,229 |
$7K |
| 90651 |
|
217 |
207 |
$5K |
| 90697 |
|
1,979 |
1,920 |
$5K |
| 98960 |
|
144 |
93 |
$2K |
| 90686 |
|
1,145 |
1,115 |
$2K |
| 83655 |
|
92 |
91 |
$1K |
| 90696 |
|
608 |
592 |
$1K |
| 99383 |
|
18 |
13 |
$1K |
| 90685 |
|
121 |
115 |
$919.74 |
| 90715 |
|
454 |
435 |
$916.21 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
157 |
128 |
$577.24 |
| 90700 |
|
326 |
317 |
$406.69 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
533 |
504 |
$314.71 |
| 96381 |
|
30 |
27 |
$295.68 |
| 85018 |
|
141 |
138 |
$282.19 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
24 |
24 |
$278.64 |
| 81003 |
|
437 |
402 |
$79.43 |
| J7614 |
Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg |
24 |
24 |
$1.08 |
| 90619 |
|
41 |
40 |
$0.00 |
| 90656 |
|
46 |
46 |
$0.00 |
| 90671 |
|
237 |
233 |
$0.00 |